Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1CXBG | ISIN: FR0010557264 | Ticker-Symbol: A8D
Tradegate
27.06.25 | 16:23
1,424 Euro
+1,28 % +0,018
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
AB SCIENCE SA Chart 1 Jahr
5-Tage-Chart
AB SCIENCE SA 5-Tage-Chart
RealtimeGeldBriefZeit
1,3961,41613:03
1,3961,41427.06.

Aktuelle News zur AB SCIENCE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoAB Science: New Peer-Reviewed Masitinib Trial Shows Strong Evidence Supporting Potential To Treat AD279PARIS (dpa-AFX) - French pharmaceutical company AB Science SA (ABSCF.PK) announced Monday that a new peer-reviewed data provide strong evidence supporting Masitinib's potential for the treatment...
► Artikel lesen
AB SCIENCE Aktie jetzt für 0€ handeln
MoAB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer's disease108PRESS RELEASE NEW PEER-REVIEWED DATA PROVIDE STRONG EVIDENCE SUPPORTING MASITINIB'S POTENTIAL FOR THE TREATMENT OF ALZHEIMER'S DISEASE THROUGH A DUAL MECHANISM OF COGNITIVE ENHANCEMENT AND NEUROPROTECTION...
► Artikel lesen
09.06.AB Science: EMA Approves Shelf-Life Extension For MASIVET To 48 Months341PARIS (dpa-AFX) - AB Science (ABSCF.PK) announced that the European Medicines Agency (EMA) has approved an extension of the shelf life of its veterinary medicine, MASIVET, to 48 months from...
► Artikel lesen
09.06.AB Science announces EMA approval of Masivet shelf-life extension to 4 years113PRESS RELEASE AB SCIENCE ANNOUNCES EMA APPROVAL OF MASIVET® SHELF-LIFE EXTENSION TO 4 YEARS Paris, June 9, 2025, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the European...
► Artikel lesen
23.05.AB Science announces the settlement delivery of its latest capital increase for €1.8 million127PRESS RELEASE AB SCIENCE ANNOUNCES THE SETTLEMENT DELIVERY OF ITS LATEST CAPITAL INCREASE FOR €1.8 MILLION Paris, May 23, 2025, 8am CET AB Science S.A. (the "Company" or "AB Science", Euronext...
► Artikel lesen
20.05.AB Science announces the successful completion of a EUR 1.8 million private placement5
19.05.AB Science Receives Chinese Patent Protecting Masitinib To Treat Covid-19 Until 2041; Stock Up303BEIJING (dpa-AFX) - French pharmaceutical company AB Science SA (ABSCF.PK) announced Monday that it has received Chinese patent protecting Masitinib in the treatment of Covid-19 until April...
► Artikel lesen
19.05.AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection127PRESS RELEASE AB SCIENCE RECEIVES CHINESE PATENT PROTECTING MASITINIB IN THE TREATMENT OF COVID-19 UNTIL 2041, ADDING ONE MORE INDICATION WITH LONG TERM INTELLECTUAL PROPERTY PROTECTION Paris, May...
► Artikel lesen
15.05.AB Science today reports a new publication in the scientific journal PLOS One, showing promising neuroprotective effects of masitinib2
12.05.AB Science Posts Narrower Loss In FY24253BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - AB Science SA (ABSCF.PK) posted a fiscal 2024 net loss of 7.8 millon euros compared to a loss of 12.0 million euros, prior year. Basic loss per share was...
► Artikel lesen
12.05.AB Science reports its revenues for the year 2024 and provides an update on its activities854PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 2024 AND THE KEY EVENTS OF THE PERIOD Financial and corporate situation Operating deficit of 6,1 million euros...
► Artikel lesen
05.05.AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual Meeting1
01.05.AB Science will publish its 2024 annual financial report on May 9, 20252
23.04.AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia279PRESS RELEASE EUROPEAN MEDICINES AGENCY (EMA) HAS GRANTED ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR AB8939 IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA Paris, April 23, 2025, 6.45pm CET AB Science...
► Artikel lesen
14.04.AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell disease252PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR UNITED STATES PATENT COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL DISEASE Paris, April 14, 2025, 6pm CET AB Science SA (Euronext...
► Artikel lesen
04.03.AB Science: Article from the leading publication Life Sciences Magazine featuring masitinib and its Phase 3 principal investigator, the neurologist Patrick Vermersch190PRESS RELEASE ARTICLE FROM THE LEADING PUBLICATION LIFE SCIENCES MAGAZINE FEATURING AB SCIENCE'S MASITINIB AND ITS PHASE 3 PRINCIPAL INVESTIGATOR, THE NEUROLOGIST PATRICK VERMERSCH Paris, March 04...
► Artikel lesen
29.01.AB Science today provides an update on its masitinib platform5
24.01.AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET2
28.10.24AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease2.321PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL DISEASE THIS DECISION FURTHER STRENGTHENS MASITINIB'S...
► Artikel lesen
17.10.24AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS222PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Paris, 17 October, 2024, 7.30pm...
► Artikel lesen
Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1